Fig. 2.
Distribution of day 3 positivity after treatment with artemisinin-based combination therapy (ACT) and molecular markers (k13, pfarps10, pffd and pfmdr2) in six sentinel sites. Day 3 prevalence and high mutant rate of molecular markers were observed in southern Myanmar sites, Myanmar Artemisinin Resistance Containment (MARC) Tier I areas